Prihlásiť sa Zaregistrujte sa zadarmo

Výplatný pomer spoločnosti Æterna Zentaris

Aká je hodnota metriky Výplatný pomer spoločnosti Æterna Zentaris?

Hodnota metriky Výplatný pomer spoločnosti Æterna Zentaris, Inc. je 0.00%

Aká je definícia metriky Výplatný pomer?



Výplatný pomer (Payout ratio) je pomer výnosov vyplatených akcionárom ku všetkým výnosom.

The payout ratio is calculated by dividing the dividends paid out by the net earnings for a certain period. It is usually expressed as a percentage. The part of the earnings not paid to investors is left for investment to provide for future earnings growth. Investors seeking high current income and limited capital growth prefer companies with high payout ratio. However investors seeking capital growth may prefer lower payout ratio because capital gains are taxed at a lower rate. High growth firms in early life generally have low or zero payout ratios. As they mature, they tend to return more of the earnings back to investors.

Výplatný pomer spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou Æterna Zentaris

Čomu sa venuje spoločnosť Æterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Firmy s metrikou výplatný pomer podobnou spoločnosti Æterna Zentaris